1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Building A US Business: Celltrion’s New CCO Talks Strategy

Biosimilars Specialist Moves To Direct Sales Model In US With Three Key Launches

 
• By Dave Wallace

With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.

Jigsaw puzzle of US flag
Tom Nusbickel has been piecing together Celltrion’s US operation • Source: Shutterstock

Celltrion is not new to the US biosimilars market. For years, the company has partnered with other leading firms – including Pfizer Inc. and Teva Pharmaceutical Industries Ltd. – to market its biosimilars in the US, notching up achievements that have included launching the first US biosimilar monoclonal antibody, with Inflectra (infliximab-dyyb), as well as offering the first Rituxan (rituximab) rival to boast a key rheumatoid arthritis indication. (Also see "Teva And Celltrion Gain Arthritis Advantage On Rituximab" - Generics Bulletin, 6 May, 2020.)

However, a significant change is now on the horizon for Celltrion, as it transitions to a direct sales model for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

More from Leadership

Rising Leaders 2025: Neha Krishnamohan On Readying For Uncertainty In Biotech

 
• By Meredith Landry

Neha Krishnamohan, CFO of Artiva Biotherapeutics, brings Wall Street precision to biotech innovation, helping lead the company through a successful IPO while advancing NK cell therapies for cancer and autoimmune diseases.

Rising Leaders 2025: J&J’s June Lanoue On Working With A Cure In Mind

 
• By Jo Shorthouse

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy